First Generic Alternative to Eliquis® Now Available in Canada
Jul 20, 2022TORONTO, June 20, 2022 /CNW/ - Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-Apixaban™ tablets, Canada's first generic alternative to Eliquis®.
Apotex's apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots. Available in 2.5 mg and 5mg tablets, this product comes in multiple package sizes including 60, 180, and 500 BTL.
"It is with great pride that we launch APO-Apixaban™," said Raymond Shelley, SVP, Commercial Operations, Canada & Rest of World Markets. "Gaining access to a generic option of an important medication like Eliquis® provides patients with more affordable opportunities for the treatment of blood clots."
Anticoagulants, also known as blood thinners, are administered to patients who are at a high risk of getting blood clots, to reduce their chances of developing serious conditions such as strokes and heart attacks. APO-Apixaban™ adds to our anticoagulant portfolio, which currently includes APO-Dabigatran.
We remain committed to bringing more generics to Canadian patients.
About Apotex Inc.
Apotex Inc. is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs almost 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex Inc. exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the US, Mexico, and India. Through vertical integration, Apotex is comprised of multiple divisions and affiliates including Apotex Inc., focused on generics; Apobiologix, a division of Apotex Inc. focused on biosimilars; Aveva, an affiliate of Apotex Inc. fully integrated global developer and manufacturer of complete transdermal solutions; and Global Active Pharmaceutical Ingredients (GAPI), a division of Apotex Inc. focused on the manufacturing of active pharmaceutical ingredients (API) for Apotex and third parties. For more information visit: www.apotex.com.
Eliquis® is registered trademark owned by Bristol-Myers Squibb Holdings.
APO-Apixaban™ is a trademark owned by Apotex Inc.
APOTEX, APO and Apobiologix are registered trademarks owned by Apotex Inc.
SOURCE Apotex Inc.
For all media inquiries, please contact:
Jordan Berman
Vice-President, Global Corporate Affairs
PH: 416-401-7487
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 5, 2026
Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, October 5, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today the closing of the previously announced offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 29, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").